Log In
BCIQ
Print this Print this
 

Immunobladder intravesical

  Manage Alerts
Collapse Summary General Information
Company Japan BCG Laboratory Ltd.
DescriptionIntravesical BCG suspension
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic Modality 
Latest Stage of DevelopmentMarketed
Standard IndicationBladder cancer
Indication DetailsTreat carcinoma in situ(CIS) of the urinary bladder; Treat TaT1 bladder cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today